Piramal Finance (PIRAMALFIN) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
30 Jan, 2026Executive summary
Unaudited standalone financial results for the quarter and half year ended September 30, 2024, were approved by the Board on October 23, 2024.
Appointment of Ms. Urmila Rao as Company Secretary & Compliance Officer was confirmed.
Financial highlights
Total income for Q2 FY25 was ₹183,753 lakhs, up from ₹166,310 lakhs in Q1 FY25 and ₹173,782 lakhs in Q2 FY24.
Net profit after tax for Q2 FY25 was ₹4,660 lakhs, compared to ₹3,655 lakhs in Q1 FY25 and ₹5,127 lakhs in Q2 FY24.
Earnings per share (basic and diluted) for Q2 FY25 stood at ₹0.02, unchanged from Q1 FY25 and Q2 FY24.
Total comprehensive income for Q2 FY25 was ₹7,121 lakhs, up from ₹5,040 lakhs in Q2 FY24.
Outlook and guidance
The company is transitioning from a Housing Finance Company (HFC) to a Non-Banking Finance Company – Investment and Credit Company (NBFC-ICC) due to not meeting the Principal Business Criteria for HFCs.
Application for conversion was submitted to RBI in May 2024; compliance with HFC regulations continues until new certification is received.
Latest events from Piramal Finance
- AUM up 23% YoY to ₹96,690 Cr, with strong profitability and stable asset quality.PIRAMALFIN
Investor presentation20 Mar 2026 - AUM up 22% YoY, net profit doubled, retail at 82%, stable risk and full NCD cover.PIRAMALFIN
Q2 25/2630 Jan 2026 - Quarterly net profit reached Rs. 3,655 lakhs as the company transitions to NBFC-ICC status.PIRAMALFIN
Q1 24/2530 Jan 2026 - Net loss in Q3 FY25 despite higher income; regulatory conversion and capital cover remain key.PIRAMALFIN
Q3 24/2530 Jan 2026 - Net profit returned to positive, NBFC-ICC conversion completed, and capital base strengthened.PIRAMALFIN
Q4 24/2530 Jan 2026 - Q1 FY26 net profit surged to ₹93.98 crore on revenue of ₹2,256.26 crore.PIRAMALFIN
Q1 25/2630 Jan 2026 - Q3 FY26 saw 23% AUM growth, ₹401.01 Cr net profit, and strong asset cover.PIRAMALFIN
Q3 25/2630 Jan 2026